Sarcopenia is a negative prognostic factor in localized extremities/trunk wall soft tissue sarcomas. in European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology / Eur J Surg Oncol. 2025 Mar 7;51(7):109746. doi: 10.1016/j.ejso.2025.109746.

2025
ASL Città di Torino
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Tipo pubblicazione

Journal Article

Autori/Collaboratori (19)Vedi tutti...

Grignani G
Oncologia Medica, AOU Città della Salute e della Scienza di Torino, Italy; Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy.
Piana R
Ortopedia Oncologica, Ospedale CTO, AOU Città della Salute e della Scienza di Torino, Italy.
Levis M
Università degli Studi di Torino Dipartimento di Oncologia, Italy; Radioterapia, AOU Città della Salute e della Scienza di Torino, Italy.

et alii...

Abstract

OBJECTIVE: Sarcopenia is an emerging determinant of oncologic patients' prognosis, but few data are available in extremities and trunk wall soft tissue sarcomas (ESTS). The aim was to evaluate sarcopenia impact on outcomes of patients affected by ESTS. METHODS: Through SliceOMatic software we selected cross-sectional skeletal muscle area (SMA), subcutaneous fat area (SFA) and visceral fat area (VFA) on a basal CT-slice at level of the third lumbar vertebra. Muscle density (MD) was computed in Hounsfield units (HU). Skeletal mass index (SMI, cm(2)/m(2)) was computed by normalizing SMA for the square of patient's height. Cut-offs for SMI were 52 and 39 cm(2)/m(2) for men and women, respectively, while we used median values for MD, SFA and VFA. We explored the correlation of the different parameters with post-surgical complications and survival outcomes (Kaplan-Meier method). RESULTS: 268 patients were included. Median SMAs, SMIs and MD were 155.7 cm(2), 51.2 cm(2)/m(2), and 33.8 HU for men, 91.4 cm(2), 39.2 cm(2)/m(2), and 30.4 HU for women. Sarcopenia rate was not significantly higher in patients ?65 years nor according to baseline prognostic factors (Sarculator app). Overall survival (OS) was significantly worse for sarcopenic patients: median OS 111.7 months (95%CI 72.8-150.6) vs not reached (NR; HR = 1.55, 95%CI:1.00-2.41, p = 0.049) for low-vs high-SMI; median OS 79.6 months (38.6-120.6) vs NR (HR 2.11, 1.34-3.34, p = 0.001) for low-vs high-MD, respectively. Sarcopenic patients showed increased post-surgical complications (30.5 % vs 17.0 %, p = 0.073). CONCLUSION: Although retrospective, our study suggests to further explore sarcopenia as a negative prognostic factor in ESTS patients.

Accesso banca dati bibliografica

PMID : 40120351

DOI : 10.1016/j.ejso.2025.109746

Keywords

Soft tissue sarcomas; Skeletal mass index; Sarcopenia; Prognostic factors; Oncology; Muscle density;